Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies

Sukhov, 2016, Interactions of the immune system with skin and bone tissue in psoriatic arthritis: a comprehensive review, Clin. Rev. Allergy Immunol., 51, 87, 10.1007/s12016-016-8529-8 Raychaudhuri, 2014, Diagnosis and classification of psoriasis, Autoimmun. Rev., 13, 490, 10.1016/j.autrev.2014.01.008 Machado, 2014, Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis, Best Pract. Res. Clin. Rheumatol., 28, 711, 10.1016/j.berh.2014.10.004 Mease, 2011, Arthritis Care & Res., 63, S64, 10.1002/acr.20577 Kauffman, 2004, A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis, J. Investig. Dermatol., 123, 1037, 10.1111/j.0022-202X.2004.23448.x Litinsky, 2016, Ultrasound assessment of enthesis thickening in psoriatic arthritis patients treated with adalimumab compared to methotrexate, Clin. Rheumatol., 35, 363, 10.1007/s10067-014-2753-5 Atteno, 2010, Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs, Clin. Rheumatol., 29, 399, 10.1007/s10067-009-1340-7 Duarte, 2012, Psoriatic arthritis, Best Pract. Res. Clin. Rheumatol., 26, 147, 10.1016/j.berh.2012.01.003 Hong, 2015, A method for comprehensive glycosite-mapping and direct quantitation of serum glycoproteins, J. Proteome Res., 14, 5179, 10.1021/acs.jproteome.5b00756 Maverakis, 2015, Glycans in the immune system and the altered glycan theory of autoimmunity: a critical review, J. Autoimmun., 57, 1, 10.1016/j.jaut.2014.12.002 Generali, 2016, Biomarkers in psoriatic arthritis: a systematic literature review, Expert Rev. Clin. Immunol., 12, 651, 10.1586/1744666X.2016.1147954 Girolomoni, 2009, Psoriasis and systemic inflammation: underdiagnosed enthesopathy, J. Eur. Acad. Dermatol. Venereol., 23, 3, 10.1111/j.1468-3083.2009.03361.x Liu, 2014, Psoriatic arthritis: Epidemiology, diagnosis, and treatment, World J. Orthop., 5, 537, 10.5312/wjo.v5.i4.537 Husni, 2007, The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool, J. Am. Acad. Dermatol., 57, 581, 10.1016/j.jaad.2007.04.001 Ibrahim, 2009, Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire, Clin. Exp. Rheumatol., 27, 469 Chandran, 2011, Toronto Psoriatic Arthritis Screening (ToPAS) questionnaire: a report from the GRAPPA 2009 annual meeting, J. Rheumatol., 38, 546, 10.3899/jrheum.101117 Taylor, 2006, Classification criteria for psoriatic arthritis: development of new criteria from a large international study, Arthritis Rheum., 54, 2665, 10.1002/art.21972 Zlatkovic-Svenda, 2013, Psoratic arthritis classification criteria: moll and Wright, ESSG and CASPAR – a comparative study, Acta Reumatol. Port., 38, 172 Coates, 2012, Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis, Arthritis Rheum., 64, 3150, 10.1002/art.34536 Fransen, 2006, Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors, Ann. Rheum. Dis., 65, 1373, 10.1136/ard.2006.051706 Felson, 1995, American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis, Arthritis Rheum., 38, 727, 10.1002/art.1780380602 van Gestel, 1996, Arthritis Rheum., 39, 34, 10.1002/art.1780390105 Coates, 2013, Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease, Arthritis Rheum., 65, 1504, 10.1002/art.37939 Gladman, 2007, Consensus on a core set of domains for psoriatic arthritis, J. Rheumatol., 34, 1167 Kilic, 2015, Comparison of ASDAS and BASDAI as a measure of disease activity in axial psoriatic arthritis, Clin. Rheumatol., 34, 515, 10.1007/s10067-014-2734-8 Helliwell, 2012, GRAPPA Responder Index Project (GRACE): a report from the GRAPPA 2011 annual meeting, J. Rheumatol., 39, 2196, 10.3899/jrheum.120822 Mease, 2011, Psoriatic arthritis: update on pathophysiology, assessment and management, Ann. Rheum. Dis., 70, i77, 10.1136/ard.2010.140582 Schoels, 2010, Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis, Ann. Rheum. Dis., 69, 1441, 10.1136/ard.2009.122259 Gladman, 2010, Informing response criteria for psoriatic arthritis. I: discrimination models based on data from 3 anti-tumor necrosis factor randomized studies, J. Rheumatol., 37, 1892, 10.3899/jrheum.091172 Gladman, 2010, Informing response criteria for psoriatic arthritis (PsA). II: further considerations and a proposal–the PsA joint activity index, J. Rheumatol., 37, 2559, 10.3899/jrheum.100479 Mumtaz, 2011, Development of a preliminary composite disease activity index in psoriatic arthritis, Ann. Rheum. Dis., 70, 272, 10.1136/ard.2010.129379 FitzGerald, 2012, Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set, Ann. Rheum. Dis., 71, 358, 10.1136/annrheumdis-2011-200093 Coates, 2010, Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment, Ann. Rheum. Dis., 69, 48, 10.1136/ard.2008.102053 Helliwell, 2013, The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project), Ann. Rheum. Dis., 72, 986, 10.1136/annrheumdis-2012-201341 Helliwell, 2011, Composite measures in psoriatic arthritis: a report from the GRAPPA 2009 annual meeting, J. Rheumatol., 38, 540, 10.3899/jrheum.101116 Gossec, 2012, European League against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies, Ann. Rheum. Dis., 71, 4, 10.1136/annrheumdis-2011-200350 Ritchlin, 2009, Treatment recommendations for psoriatic arthritis, Ann. Rheum. Dis., 68, 1387, 10.1136/ard.2008.094946 Gossec, 2016, European League against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update, Ann. Rheum. Dis., 75, 499, 10.1136/annrheumdis-2015-208337 Ash, 2012, A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis, Ann. Rheum. Dis., 71, 319, 10.1136/ard.2011.150995 Coates, 2016, Group for research and assessment of psoriasis and psoriatic arthritis 2015 Treatment recommendations for psoriatic arthritis, Arthritis Rheumatol., 68, 1060 Raychaudhuri, 2012, Comorbidities of psoriatic arthritis – metabolic syndrome and prevention: a report from the GRAPPA 2010 annual meeting, J. Rheumatol., 39, 437, 10.3899/jrheum.111244 Gelfand, 2006, Risk of myocardial infarction in patients with psoriasis, JAMA J. Am. Med. Assoc., 296, 1735, 10.1001/jama.296.14.1735 Raychaudhuri, 2010, Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis, Metab. Syndr. Relat. Disord., 8, 331, 10.1089/met.2009.0124 Kimhi, 2007, Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis, Sem. Arthritis Rheum., 36, 203, 10.1016/j.semarthrit.2006.09.001 Gladman, 2009, Cardiovascular morbidity in psoriatic arthritis, Ann. Rheum. Dis., 68, 1131, 10.1136/ard.2008.094839 Muna, 1980, Psoriatic arthritis and aortic regurgitation, JAMA J. Am. Med. Assoc., 244, 363, 10.1001/jama.1980.03310040045027 Khan, 2002, Update on spondyloarthropathies, Ann. Intern. Med., 136, 896, 10.7326/0003-4819-136-12-200206180-00011 Farber, 1997, Concept of total care: a third dimension in the treatment of psoriasis, Cutis, 59, 35 Meyerhoff, 1983, Exacerbation of psoriasis with meclofenamate, N. Engl. J. Med., 309, 496, 10.1056/NEJM198308253090816 Sarzi-Puttini, 2001, The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide, Clin. Exp. Rheumatol., 19, S17 Kivitz, 2007, A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis, Sem. Arthritis Rheum., 37, 164, 10.1016/j.semarthrit.2007.03.004 Joshi, 2014, An update on disease modifying antirheumatic drugs, Inflamm. Allergy Drug Targets, 13, 249, 10.2174/187152811304140915152102 Cipriani, 2014, Methotrexate: an old new drug in autoimmune disease, Expert Rev. Clin. Immunol., 1 Kingsley, 2012, A randomized placebo-controlled trial of methotrexate in psoriatic arthritis, Rheumatology, 51, 1368, 10.1093/rheumatology/kes001 Huynh, 2015, Psoriatic arthritis: current therapy and future approaches, Rheumatology, 54, 20, 10.1093/rheumatology/keu237 Lie, 2010, Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis, Ann. Rheum. Dis., 69, 671, 10.1136/ard.2009.113308 Willkens, 1984, Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis, Arthritis Rheum., 27, 376, 10.1002/art.1780270403 Abu-Shakra, 1995, Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome, J. Rheumatol., 22, 241 Guidelines for monitoring drug therapy in rheumatoid arthritis, 1996, American College of rheumatology ad Hoc Committee on clinical guidelines, Arthritis Rheum., 39, 723 Breedveld, 2000, Leflunomide: mode of action in the treatment of rheumatoid arthritis, Ann. Rheum. Dis., 59, 841, 10.1136/ard.59.11.841 Kaltwasser, 2004, Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial, Arthritis Rheum., 50, 1939, 10.1002/art.20253 Nash, 2006, Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study, Dermatology, 212, 238, 10.1159/000091251 Kaltwasser, 2004, Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial, Arthritis Rheum., 50, 1939, 10.1002/art.20253 Ramiro, 2014, Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis, Ann. Rheum. Dis., 73, 529, 10.1136/annrheumdis-2013-204575 Nielsen, 1987, Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid, Dig. Dis. Sci., 32, 577, 10.1007/BF01296156 Combe, 1996, Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study, Br. J. Rheumatol., 35, 664, 10.1093/rheumatology/35.7.664 Farr, 1990, Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study, Br. J. Rheumatol., 29, 46, 10.1093/rheumatology/29.1.46 Fraser, 1993, Sulphasalazine in the management of psoriatic arthritis, Br. J. Rheumatol., 32, 923, 10.1093/rheumatology/32.10.923 Gupta, 1995, Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial, J. Rheumatol., 22, 894 Dougados, 1995, Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study, Arthritis Rheum., 38, 618, 10.1002/art.1780380507 Clegg, 1996, Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative study, Arthritis Rheum., 39, 2004, 10.1002/art.1780391209 Menter, 2009, Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents, J. Am. Acad. Dermatol., 61, 451, 10.1016/j.jaad.2009.03.027 Fraser, 2005, A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis, Ann. Rheum. Dis., 64, 859, 10.1136/ard.2004.024463 Salvarani, 2001, A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis, J. Rheumatol., 28, 2274 Mahrle, 1996, Anti-inflammatory efficacy of low-dose cyclosporin A in psoriatic arthritis. A prospective multicentre study, Br. J. Dermatol., 135, 752, 10.1111/j.1365-2133.1996.tb03885.x Levy, 1972, A double-blind controlled evaluation of azathioprine treatment in the rheumatoid arthritis and psoriatic arthritis, Arthritis Rheum., 15 Lee, 2001, The long-term use of azathioprine in patients with psoriatic arthritis, J. Clin. Rheumatol. Pract. Rep. Rheum. Musculoskelet. Dis., 7, 160 Gravani, 2014, Synthetic antimalarial drugs and the triggering of psoriasis – do we need disease-specific guidelines for the management of patients with psoriasis at risk of malaria?, Int. J. Dermatol., 53, 327, 10.1111/ijd.12231 Gladman, 1992, Chloroquine therapy in psoriatic arthritis, J. Rheumatol., 19, 1724 Sivamani, 2013, Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring, Clin. Rev. Allergy & Immunol., 44, 121, 10.1007/s12016-012-8301-7 Neregard, 2014, Etanercept decreases synovial expression of tumour necrosis factor-alpha and lymphotoxin-alpha in rheumatoid arthritis, Scand. J. Rheumatol., 43, 85, 10.3109/03009742.2013.834964 Menter, 2008, Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics, J. Am. Acad. Dermatol., 58, 826, 10.1016/j.jaad.2008.02.039 Antoni, 2005, Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT), Arthritis Rheum., 52, 1227, 10.1002/art.20967 Kavanaugh, 2006, The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year, Ann. Rheum. Dis., 65, 1038, 10.1136/ard.2005.045658 Mease, 2005, Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial, Arthritis Rheum., 52, 3279, 10.1002/art.21306 Gladman, 2007, Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial, Arthritis Rheum., 56, 476, 10.1002/art.22379 Mease, 2004, Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression, Arthritis Rheum., 50, 2264, 10.1002/art.20335 Saurat, 2008, Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION), Br. J. Dermatol., 158, 558, 10.1111/j.1365-2133.2007.08315.x Shupack, 1997, Cyclosporine as maintenance therapy in patients with severe psoriasis, J. Am. Acad. Dermatol., 36, 423, 10.1016/S0190-9622(97)80219-8 Leonardi, 2003, Etanercept as monotherapy in patients with psoriasis, N. Engl. J. Med., 349, 2014, 10.1056/NEJMoa030409 Tyring, 2006, Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial, Lancet, 367, 29, 10.1016/S0140-6736(05)67763-X Reich, 2005, Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial, Lancet, 366, 1367, 10.1016/S0140-6736(05)67566-6 Mease, 2006, Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept, J. Rheumatol., 33, 712 Sterry, 2010, Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial, BMJ, 340, c147, 10.1136/bmj.c147 Antoni, 2005, Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial, Ann. Rheum. Dis., 64, 1150, 10.1136/ard.2004.032268 van der Heijde, 2007, Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2, Arthritis Rheum., 56, 2698, 10.1002/art.22805 Baranauskaite, 2012, Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study, Ann. Rheum. Dis., 71, 541, 10.1136/ard.2011.152223 Mease, 2009, Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT), Ann. Rheum. Dis., 68, 702, 10.1136/ard.2008.092767 Genovese, 2007, Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy, J. Rheumatol., 34, 1040 Karanikolas, 2011, Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial, J. Rheumatol., 38, 2466, 10.3899/jrheum.110242 Kavanaugh, 2009, Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study, Arthritis Rheum., 60, 976, 10.1002/art.24403 Kavanaugh, 2012, Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial, Arthritis Rheum., 64, 2504, 10.1002/art.34436 Kavanaugh, 2014, Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study), Ann. Rheum. Dis., 73, 1689, 10.1136/annrheumdis-2013-204902 Olivieri, 2014, Advances in the management of psoriatic arthritis, Nat. Rev. Rheumatol., 10, 531, 10.1038/nrrheum.2014.106 Mease, 2014, Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA), Ann. Rheum. Dis., 73, 48, 10.1136/annrheumdis-2013-203696 van der Heijde, 2014, Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol, Ann. Rheum. Dis., 73, 233, 10.1136/annrheumdis-2013-203697 Tausend, 2014, Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab, J. Cutan. Med. Surg., 18, 156, 10.2310/7750.2013.13125 Leipe, 2010, Role of Th17 cells in human autoimmune arthritis, Arthritis Rheum., 62, 2876, 10.1002/art.27622 Chan, 2006, IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis, J. Exp. Med., 203, 2577, 10.1084/jem.20060244 Leonardi, 2008, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1), Lancet, 371, 1665, 10.1016/S0140-6736(08)60725-4 Griffiths, 2010, Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis, N. Engl. J. Med., 362, 118, 10.1056/NEJMoa0810652 Gottlieb, 2009, Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial, Lancet, 373, 633, 10.1016/S0140-6736(09)60140-9 McInnes, 2013, Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial, Lancet, 382, 780, 10.1016/S0140-6736(13)60594-2 Kavanaugh, 2013, Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 2 year results from a phase 3, multicenter, double-blind, placebo-controlled study [abstract], Arthritis Rheum., 65, L10 Ritchlin, 2014, Ann. Rheum. Dis., 73, 990, 10.1136/annrheumdis-2013-204655 Raychaudhuri, 2012, IL-17 receptor and its functional significance in psoriatic arthritis, Mol. Cell Biochem., 359, 419, 10.1007/s11010-011-1036-6 Adamopoulos, 2015, IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis, Ann. Rheum. Dis., 74, 1284, 10.1136/annrheumdis-2013-204782 Papp, 2012, Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis, N. Engl. J. Med., 366, 1181, 10.1056/NEJMoa1109017 Langley, 2014, Secukinumab in plaque psoriasis–results of two phase 3 trials, N. Engl. J. Med., 371, 326, 10.1056/NEJMoa1314258 Gordon, 2014, A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis, J. Am. Acad. Dermatol., 71, 1176, 10.1016/j.jaad.2014.07.048 McInnes, 2014, Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial, Ann. Rheum. Dis., 73, 349, 10.1136/annrheumdis-2012-202646 Mease, 2014, Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis, N. Engl. J. Med., 370, 2295, 10.1056/NEJMoa1315231 ClinicalTrials.gov. A Study of Ixekizumab in Participants With Active Psoriatic Arthritis. SPIRIT-P1: Identifier:NCT01695239. ClinicalTrials.gov. Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis. ClinicalTrials.gov Identifier:NCT02429882. ClinicalTrials.gov. Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-2). ClinicalTrials.gov Identifier:NCT01708603. ClinicalTrials.gov. Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis (AMVISION-2). ClinicalTrials.gov Identifier: NCT02024646. Gottleib, 2013, Secukinumab shows substantial improvement in both psoriasis symptoms and physical functioning in moderate-to-severe plaque psoriasis patients with psoriatic arthritis: a subanalysis of phase 3 multicentre, double-blind, placebo-controlled study [abstract], Arthritis Rheum., 65 McInnes, 2015, Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 386, 1137, 10.1016/S0140-6736(15)61134-5 Griffiths, 2015, Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials, Lancet, 386, 541, 10.1016/S0140-6736(15)60125-8 Houslay, 2005, Keynote review: phosphodiesterase-4 as a therapeutic target, Drug Discov. Today, 10, 1503, 10.1016/S1359-6446(05)03622-6 Schafer, 2014, Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity, Cell. Signal., 26, 2016, 10.1016/j.cellsig.2014.05.014 Schafer, 2010, Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis, Br. J. Pharmacol., 159, 842, 10.1111/j.1476-5381.2009.00559.x Mease, 2013, Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: pooled safety analysis of three phase 3, randomized, controlled trials [abstract], Arthritis Rheum., 65, 131 Cutolo, 2013, Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic aethritis (PALACE 2) [abstract], Arthritis Rheum., 65, 346 Edwards, 2013, Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement (PALACE 3) [abstract], Arthritis Rheum., 65, 132 Wells, 2013, Apremilast in the treatment of DMARD naïve psoriatic arthritis patients: results of a phase 3 randomized controlled trial (PALACE 4) [abstract], Arthritis Rheum., 65, L4 Schett, 2013, Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in physical function in patients with psoriatic arthritis results from three phase 3, randomized, controlled trials [abstract], Arthritis Rheum., 65, 143 Cutolo, 2013, Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in tender and swollen joint counts in patients with psoriatic arthritis: results from three phase 3, randomized, controlled trials [abstract], Arthritis Rheum., 65, 135 Kavanaugh, 2014, Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor, Ann. Rheum. Dis., 73, 1020, 10.1136/annrheumdis-2013-205056 Lee, 2014, Tofacitinib versus methotrexate in rheumatoid arthritis, N. Engl. J. Med., 370, 2377, 10.1056/NEJMoa1310476 van Vollenhoven, 2012, Tofacitinib or adalimumab versus placebo in rheumatoid arthritis, N. Engl. J. Med., 367, 508, 10.1056/NEJMoa1112072 Boy, 2009, Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis, J. Investig. Dermatol., 129, 2299, 10.1038/jid.2009.25 Papp, 2012, Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study, Br. J. Dermatol., 167, 668, 10.1111/j.1365-2133.2012.11168.x Sercarz, 2003, Mhc-guided processing: binding of large antigen fragments, Nat. Rev. Immunol., 3, 621, 10.1038/nri1149 Iannone, 2012, The inhibitor of costimulation of T cells: abatacept, J. Rheumatol. Suppl., 89, 100, 10.3899/jrheum.120257 Abrams, 1999, CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris, J. Clin. Investig., 103, 1243, 10.1172/JCI5857 Mease, 2011, Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial, Arthritis Rheum., 63, 939, 10.1002/art.30176 Raychaudhuri, 2011, Nerve growth factor: a key local regulator in the pathogenesis of inflammatory arthritis, Arthritis Rheum., 63, 3243, 10.1002/art.30564 Raychaudhuri, 2004, K252a, a high-affinity nerve growth factor receptor blocker, improves psoriasis: an in vivo study using the severe combined immunodeficient mouse-human skin model, J. Investig. Dermatol., 122, 812, 10.1111/j.0022-202X.2003.12602.x Raychaudhuri, 2009, NGF and its receptor system: a new dimension in the pathogenesis of psoriasis and psoriatic arthritis, Ann. N. Y. Acad. Sci., 1173, 470, 10.1111/j.1749-6632.2009.04652.x Bauer, 2015, Targeting PI3 kinase in cancer, Pharmacol. Ther., 146, 53, 10.1016/j.pharmthera.2014.09.006 Raychaudhuri, 2014, mTOR signaling cascade in psoriatic disease: double kinase mTOR inhibitor a novel therapeutic target, Indian J. Dermatol., 59, 67, 10.4103/0019-5154.123499 Kundu-Raychaudhuri, 2014, Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis - Xenograft model, J. Autoimmun., 55, 63, 10.1016/j.jaut.2014.07.003 Detmar, 1994, Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis, J. Exp. Med., 180, 1141, 10.1084/jem.180.3.1141 Datta-Mitra, 2014, Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer, Indian J. Dermatol., 59, 632, 10.4103/0019-5154.143574 Narayanan, 2010, Improvement of psoriasis during sunitinib therapy for renal cell carcinoma, Am. J. Med. Sci., 339, 580, 10.1097/MAJ.0b013e3181dd1aa5